Introduction
Propranolol LA is a recently developed long-acting formulation of propranolol which gives therapeutic levels and clinical effect from a single daily dose (Leahey et al., 1980a; McAinsh et al., 1978) . In contrast with single daily administration of conventional propranolol, it does not cause the excessively high plasma levels shortly after ingestion that may produce adverse effects. Moreover it maintains betablockade throughout a 24-hr period (Mann et al., 1980) . This latter effect and the 24-hr control of blood pressure have been studied by the technique of ambulatory intra-arterial monitoring (Millar-Craig, 1979) . We feel that this method is unacceptably invasive and therefore have evaluated the Dinamap automatic arterial blood pressure monitor. This machine is non-invasive and easy to use. a Hawksley random zero sphygmomanometer (Silas et aL, 1980; Ramsey, 1979) . We report an open within-patient study comparing the 24-hr control of blood pressure and heart rate in hypertensive patients taking either once daily propranolol LA or twice daily propranolol.
Methods

Recording device
The Dinamap 845 measures and digitally displays the systolic, diastolic, mean arterial pressures and heart rate and the Dinamap 950 produces a graphic record of these measurements. The Dinamap was connected to a timer set to switch on for 30 min and off for 90 min and automatic measurements were made at 3-min intervals. Blood pressure alarm limits were set to a low of 20 mmHg and a high of 200 mmHg. The operation ofthe Dinamap has been fully described elsewhere (Silas et aL, 1980) .
Patients
Patients from a hospital clinic with essential hypertension were asked to participate in this trial if their clinic blood pressures were in excess of 155/90 mmHg after having stopped all antihypertensive drugs for 14 days. Five males with a mean age of 53 years (range 41-65 years) and weight 75-2 kg and five females with a mean age of 51 years (range 43-59 years) and weight 62-6 kg were recruited. Three patients had previously taken antihypertensive therapy. Patients were excluded if they had had a recent myocardial infarction, if there was evidence of cardiac failure or if there was ECG evidence of ischaemic changes or heart block. Those with obstructive airways disease, diabetes mellitus or severe hypertensive retinopathy were also excluded.
Procedure
Each patient was admitted to a single-bedded room during their first and all subsequent admis-sions, an adult Baumanometer V-Lok cuff was tightly placed around the non-dominant upper arm. This left the dominant arm free to perform vital functions whilst measuring was in progress. The cuff bladder was centred over the brachial artery and adhesive tape was applied to ensure that the cuff did not slip. Measurements of blood pressure and heart rate were made at 3-min intervals for 30 min while the patient was lying down and were repeated every 2 hr. After each period of recording, patients were encouraged to be ambulant but had to be supine again 30 min before measuring restarted. During the 24 hr, the cuff was kept on the arm and the patient simply reconnected the tubes on lying down and went to sleep with the tubes connected.
Following the 24-hr monitoring, each patient was exercised on a bicycle ergometer to achieve a tachycardia greater than 100 beats per min. The grade and duration of exercise were recorded so that the same exercise challenge could be repeated on future admissions. The exercise tests were done at the same time on each admission and approximately 3-4 hr after administration of propranolol or long-acting propranolol.
Patients were started on propranolol 40 mg twice daily and assessed in the clinic 2 weeks later when the blood pressure was recorded in the lying and standing positions. If the blood pressure was poorly controlled, propranolol was increased to a maximum of 320 mg daily in two doses. They were reviewed at 2-weekly intervals and if the blood pressure was still poorly controlled, a diuretic and/or vasodilator drug 
Data analysis
After each patient's admission, there were twelve sets of recordings at 2-hourly intervals. The mean values of heart rate, systolic and diastolic pressures were calculated for each period and these means were pooled according to the stage and time of the study. Circadian curves were constructed to demonstrate trends over the three 24-hr periods, before treatment, during treatment with twice daily propranolol and with once daily propranolol LA (Figs. 1 and 2) . Differences between therapies were assessed by Student's paired t-test.
Results
All patients completed the trial and no side effects Following conventional propranolol therapy, the systolic blood pressures were significantly lowered throughout the day (P<001) except at 13.00. 5.00 and 7.00 when the level of significance reached P<005. Similarly, the diastolic pressures were reduced throughout the 24 hours (P<0-01) except at times 17.00, 23.00, 5.00, 7.00 and 9.00 when the degree of statistical significance was P<0 05. Compared to pretreatment values, propranolol LA therapy lowered systolic pressures throughout the day (P<0 01) except at 9.00, 23.00, 5.00 and 7.00 when the statistical difference was P<005. The diastolic pressures were also reduced (P<0-01) apart from times 9.00, 1.00, 5.00 and 7.00 (P<0 05). There was no significant difference in the control of blood pressure between the two treatments. Heart rates were significantly reduced from control values whilst taking propranolol (P<0 05) except at times 21.00, 23.00 and 01.00 and during propranolol LA therapy (P<0 05) except time 01.00. There was no difference between the two drug regimes.
Comparison of pooled values of heart rate and blood pressure measured for 10 min before exercise and for I min after bicycle ergometry showed a significant reduction with both treatments (P<0.001) compared to pre-treatment values (Table 1) . Again, there was no significant difference between the two treatments.
Discussion
In most clinical trials assessing new antihypertensive drugs, patient's blood pressures are measured either by a mercury sphygmomanometer or by ambulatory intra-arterial monitoring. The former method suffers from observer bias, digit preference and variation between observers, especially when staff change (Fitzgerald, O'Malley and O'Brien, 1982; O'Brien and O'Malley, 1979 intra-arterial blood pressure recordings (Hunyor, Flynn and Cochineas, 1978) . Continuous ambulatory monitoring has demonstrated the striking variation in blood pressure during normal activity but unfortunately it is invasive, is unpleasant and may cause complications (Littler, 1976) . We therefore assessed the feasibility of using the Dinamap 845 for 24-hr blood pressure monitoring and were gratified to find that the circadian rythms of blood pressure we obtained closely resemble those obtained by ambulatory monitoring in hypertensive patients (Miller Craig et al., 1978a; Miller Craig, Bishop and Raftery, 1978b (Leahey et al., 1980b , Petrie et al., 1980 . Twice daily propranolol produced similar results and no significant difference between the regimes was detected. Propranolol LA produced a significant reduction in blood pressure and heart rate during bicycle ergometry tests. These tests were timed at between 3-4 hr after the last dose of propranolol LA and were not designed to test the efficacy of the drug beyond 24 hr.
This study was non-randomized because it was thought that if patients started on long-acting propranolol and their blood pressures were not controlled, an incremental rise of 160 mg would be too great and predispose them to side effects. We therefore started all patients on twice daily conventional propranolol and increased the daily dose by increments of 80 mg. This had two consequences. Firstly, because the drugs were always administered in the same order, it was not possible to separate treatment from time effects. Secondly, five patients took an equivalent dose of propranolol in the long-acting formulation but five increased their overall dose. There was no significant difference in the blood pressure control between the two groups so some patients were taking an unnecessarily high dose of propranolol in the LA formulation. Although five patients do not have great statistical power, it does seem there might be a place for a smaller-dose LA tablet.
In conclusion, we have shown that both once daily propranolol LA and twice daily conventional propranolol produce an effective and similar 24-hr control of blood pressure and heart rate in hypertensive patients. We have also demonstrated that the Dinamap non-invasive blood pressure recorder can assess blood pressure control and suggest that it may play a useful role in future trials of antihypertensive drugs.
